StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)
February 4, 2026 8:21 AM
Leerink Partners analyst David Risinger reiterated an Outperform rating and $1,234.00 price target on Eli Lilly (NYSE: LLY).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Truist: 'Defending Lilly: LLY strong position helps guard their share in a crowded GLP-1 landscape'
February 5, 2026 12:35 PM
Wells Fargo on Eli Lilly (LLY): 'Compounders Strike Again, but We See Little Risk to Near-Term Growth'
February 5, 2026 10:10 AM
